Phenylpropanoid compound as well as preparation method and application thereof
By extracting and preparing styrene compounds from Congba plants, the problem of insufficient research on secondary metabolic components of bamboo is solved, drug candidates for the treatment of nervous system and cardiovascular diseases are provided, and virtual screening technology is improved Screening efficiency.
Patent Information
- Application Number
- CN202411123987.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
AI Technical Summary
The secondary metabolic components of bamboo are less studied and cannot meet the needs of modern Chinese medicine development, especially in the discovery of new active ingredients or lead compounds.
Compounds 1, 2 and 3 were prepared by ethanol solution extraction, butanol extraction, macroporous adsorption resin column separation and chromatographic column separation, and molecular docking was used to prepare compound 1, 2 and 3. Analyze its interaction with targets with virtual screening techniques.
The successful acquisition of drug candidates for the treatment of neurological and cardiovascular diseases has reduced the time and cost of drug screening, improved screening hit rate, and revealed the mechanism of action of compounds on multiple biological processes.
Smart Images

Figure CN119019479A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of natural products and drugs, and specifically relates to phenylpropanoid compounds and preparation methods and applications thereof. Background Art
[0002] Bamboo has a long history of medicinal use in my country, and bamboo stalks, leaves and roots can all be used as medicine. Phyllostachys is the genus with the greatest economic value in the bamboo subfamily, with 70 species discovered. Among them, there are 11 species of medicinal bamboo, including P. reticulata, P. edulis, P. glauca, P. heteroclada, P. makinoi, P. nidularia, P. nigra, P. nigra var. henonis, P. sulphurea, P. violascens and P. sulphurea f. robertii, which have good therapeutic effects on symptoms such as inflammation, fever and cough.
[0003] The golden bamboo is a variant of purple bamboo, with a culm height of about 7 to 18 meters, a culm wall thickness of up to 5 mm, and very few dark brown spots on the top of the sheath. This bamboo species is widely distributed in provinces south of the Yangtze River Basin. It is one of the medicinal bamboo species. The culm part can be used as medicine, and the culm of the golden bamboo is the raw material for preparing the traditional Chinese medicine bamboo juice and bamboo shavings, which have the effects of expectoration and cough relief.
[0004] Modern pharmacological studies have shown that bamboo extracts have anti-inflammatory, anti-cancer, cholesterol-lowering, melanin-inhibiting and neuroprotective effects. The rich secondary metabolites in bamboo provide the material basis for its diverse pharmacological activities. However, there are relatively few studies on bamboo secondary metabolites, which cannot meet the requirements of the development of modern Chinese medicine. Therefore, the separation and identification of secondary metabolites of Phyllostachys plants is of great value for discovering new active ingredients or lead compounds. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a phenylpropanoid compound and a preparation method and application thereof. The present invention extracts a phenylpropanoid compound from a plant of the genus Phyllostachys, and the phenylpropanoid compound can be used to prepare drugs for treating nervous system diseases and cardiovascular diseases.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides phenylpropanoid compounds, including compound 1, compound 2 or compound 3, wherein the structural formulas of compound 1, compound 2 and compound 3 are shown in formulas 1, 2 and 3 respectively;
[0008]
[0009] The present invention also provides a method for preparing the phenylpropanoid compound described in the above technical solution, comprising the following steps:
[0010] Extracting Phyllostachys spp. plants with an ethanol solution, removing ethanol from the obtained extract to obtain an alcohol extract;
[0011] Dissolving and resuspending the alcohol extract in water, extracting with butanol, and concentrating to obtain a butanol extract;
[0012] The butanol extract is subjected to macroporous adsorption resin column separation, and eluted with water, 20% volume fraction ethanol solution, and 40% volume fraction ethanol solution in sequence, and the eluates are collected and concentrated to obtain a 20% ethanol fraction and a 40% ethanol fraction;
[0013] The 20% ethanol fraction was separated by a first ODS chromatographic column, and eluted with 5% volume fraction ethanol solution, 10% volume fraction ethanol solution, 15% volume fraction ethanol solution, 20% volume fraction ethanol solution, 25% volume fraction ethanol solution, 30% volume fraction ethanol solution, 50% volume fraction ethanol solution, and 100% ethanol in sequence, with each gradient elution of 2 to 3 BV, and each 0.1 to 0.3 BV being a fraction, and the same fractions were combined and concentrated to obtain components A1 to A10; the 40% ethanol fraction was separated by a first ODS chromatographic column, and eluted with 5% volume fraction ethanol solution, 10% volume fraction ethanol solution, 25% volume fraction ethanol solution, 30% volume fraction ethanol solution, 50% volume fraction ethanol solution, and 100% ethanol in sequence, with each gradient elution of 2 to 3 BV, and each 0.1 to 0.3 BV being a fraction, and the same fractions were combined and concentrated to obtain components A1 to A10; The alcohol part is separated by a second ODS chromatography column, and eluted with 20% volume fraction ethanol solution, 30% volume fraction ethanol solution, 35% volume fraction ethanol solution, 40% volume fraction ethanol solution, 45% volume fraction ethanol solution, 50% volume fraction ethanol solution, 60% volume fraction ethanol solution, 80% volume fraction ethanol solution, and 100% ethanol in sequence, with each gradient elution of 2 to 3 BV, and each 0.1 to 0.3 BV is a fraction, and the same fractions are combined and concentrated to obtain B1 to B9 components;
[0014] The A3 component was subjected to the first gel column chromatography separation, the mobile phase was water, and each 1 / 20 times BV was a fraction. The same fractions were combined to obtain 19 elution parts, which were represented by a to s in sequence. The fractions e and h were concentrated to obtain the A3e component and the A3h component. The B1 component was subjected to the second gel column chromatography separation, the mobile phase was water, and each 1 / 20 times BV was a fraction. The same fractions were combined to obtain 15 elution parts, which were represented by a to o in sequence. The fraction h was concentrated to obtain the B1h component.
[0015] The A3e component was dissolved in water, separated by a first preparative chromatographic column, and isocratically eluted with a 15% volume fraction methanol aqueous solution to obtain compound 1; A3h was dissolved in water, separated by a second preparative chromatographic column, and isocratically eluted with a 13% volume fraction acetonitrile aqueous solution to obtain compound 3; B1h was dissolved in water, separated by a third preparative chromatographic column, and isocratically eluted with a 15% volume fraction methanol aqueous solution to obtain compound 2.
[0016] Preferably, the leaching comprises: first leaching with a first ethanol solution, and then leaching with a second ethanol solution; the volume fraction of ethanol in the first ethanol solution is 90% to 100%; the volume fraction of ethanol in the second ethanol solution is 70% to 80%.
[0017] Preferably, the material-liquid ratio of the first leaching and the second leaching is independently 1 kg: (3-5) L, the number of the first leaching is 1-2 times, the number of the second leaching is 2-3 times, and the time of each leaching is 20-30 hours.
[0018] Preferably, the extraction is performed 2 to 5 times; the butanol is water-saturated n-butanol; the volume ratio of the butanol to the alcohol extract suspension is 1 to 3:1, and the alcohol extract suspension is obtained by dissolving and resuspending the alcohol extract in water.
[0019] Preferably, the macroporous adsorption resin column comprises an HP-20 column or an AB-8 column.
[0020] Preferably, the amounts of water, 20% volume fraction ethanol solution and 40% volume fraction ethanol solution used in the separation of the macroporous adsorption resin column are 2-3 BV, 2-3 BV and 2-3 BV respectively.
[0021] Preferably, the fillers of the gel chromatography columns of the first gel column chromatography separation and the second gel column chromatography separation are both Sephadex LH-20.
[0022] Preferably, the preparative chromatographic columns used for the first preparative chromatographic column separation, the second preparative chromatographic column separation and the third preparative chromatographic column separation are all ODS-AQ.
[0023] The present invention also provides the use of the phenylpropanoid compounds described in the above technical scheme or the phenylpropanoid compounds obtained by the above preparation method in the preparation of drugs for treating nervous system diseases or cardiovascular diseases.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] The present invention provides phenylpropanoid compounds, including compound 1, compound 2 or compound 3, wherein the structural formulas of compound 1, compound 2 and compound 3 are shown in formulas 1, 2 and 3 respectively;
[0026]
[0027]
[0028] The invention provides three phenylpropanoid compounds, wherein the phenylpropanoid compounds are extracted from plants of the genus Phyllostachys; the phenylpropanoid compounds can be used for preparing medicines for treating nervous system diseases or cardiovascular diseases.
[0029] Compound 1 of the present invention mainly participates in various biological processes such as neuroactive ligand-receptor interaction, nucleotide metabolism, and cell response to hypoxia, and has a therapeutic effect on nervous system diseases and cardiovascular diseases; Compound 2 mainly participates in various biological processes such as cell growth, angiogenesis, and cell response to hypoxia, and has a therapeutic effect on cardiovascular diseases. Compound 3 focuses on regulating cell metabolism and signal transduction functions, and also has a therapeutic effect on nervous system diseases and cardiovascular diseases.
[0030] The present invention uses molecular docking and virtual screening technology to analyze the interaction between the target and the compound, calculate the affinity between the two, and avoid blind screening. Compared with drug screening through experimental methods, it can reduce time and money costs and increase the screening hit rate. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0032] Figure 1 GO enrichment results for predicting targets of compound 1;
[0033] Figure 2 KEGG enrichment results for predicted targets of compound 1;
[0034] Figure 3 DisGeNET enrichment results for predicted targets of compound 1;
[0035] Figure 4 GO enrichment results for predicting targets of compound 2;
[0036] Figure 5 KEGG enrichment results for predicted targets of compound 2;
[0037] Figure 6 DisGeNET enrichment results for predicting targets of compound 2;
[0038] Figure 7 GO enrichment results for predicting targets of compound 3;
[0039] Figure 8 KEGG enrichment results for predicted targets of compound 3;
[0040] Fig. 9 DisGeNET enrichment results for predicted targets of compound 3. DETAILED DESCRIPTION
[0041] The present invention provides phenylpropanoid compounds, including compound 1, compound 2 or compound 3, wherein the structural formulas of compound 1, compound 2 and compound 3 are shown in formulas 1, 2 and 3 respectively;
[0042]
[0043] The present invention also provides a method for preparing the phenylpropanoid compound described in the above technical solution, comprising the following steps:
[0044] Extracting Phyllostachys spp. plants with an ethanol solution, removing ethanol from the obtained extract to obtain an alcohol extract;
[0045] Dissolving and resuspending the alcohol extract in water, extracting with butanol, and concentrating to obtain a butanol extract;
[0046] The butanol extract is subjected to macroporous adsorption resin column separation, and eluted with water, 20% volume fraction ethanol solution, and 40% volume fraction ethanol solution in sequence, and the eluates are collected and concentrated to obtain a 20% ethanol fraction and a 40% ethanol fraction;
[0047] The 20% ethanol fraction is separated by a first ODS chromatographic column, and eluted with 5% volume fraction ethanol solution, 10% volume fraction ethanol solution, 15% volume fraction ethanol solution, 20% volume fraction ethanol solution, 25% volume fraction ethanol solution, 30% volume fraction ethanol solution, 50% volume fraction ethanol solution, and 100% ethanol in sequence, with each gradient elution of 2 to 3 BV, and each 0.1 to 0.3 BV is a fraction, and the same fractions are combined and concentrated to obtain components A1 to A10; step 40% The ethanol portion is separated by a second ODS chromatographic column, and eluted with 20% volume fraction ethanol solution, 30% volume fraction ethanol solution, 35% volume fraction ethanol solution, 40% volume fraction ethanol solution, 45% volume fraction ethanol solution, 50% volume fraction ethanol solution, 60% volume fraction ethanol solution, 80% volume fraction ethanol solution, and 100% ethanol in sequence, with each gradient elution being 2 to 3 BV, and each 0.1 to 0.3 BV being a fraction, and the same fractions are combined and concentrated to obtain components B1 to B9;
[0048] The A3 component was subjected to the first gel column chromatography separation, the mobile phase was water, and each 1 / 20 times BV was a fraction. The same fractions were combined to obtain 19 elution parts, which were represented by a to s in sequence. The fractions e and h were concentrated to obtain the A3e component and the A3h component respectively. The B1 component was subjected to the second gel column chromatography separation, the mobile phase was water, and each 1 / 20 times BV was a fraction. The same fractions were combined to obtain 15 elution parts, which were represented by a to o in sequence. The fraction h was concentrated to obtain the B1h component.
[0049] The A3e component was dissolved in water, separated by a first preparative chromatographic column, and isocratically eluted with a 15% volume fraction methanol aqueous solution to obtain compound 1; A3h was dissolved in water, separated by a second preparative chromatographic column, and isocratically eluted with a 13% volume fraction acetonitrile aqueous solution to obtain compound 3; B1h was dissolved in water, separated by a third preparative chromatographic column, and isocratically eluted with a 15% volume fraction methanol aqueous solution to obtain compound 2.
[0050] In the present invention, unless otherwise specified, the materials and equipment used are commercially available products in the art.
[0051] The invention uses an ethanol solution to extract the Phyllostachys genus plant, removes ethanol from the obtained extract, and obtains an alcohol extract.
[0052] In the present invention, the plant of the genus Phyllostachys preferably includes one of P. nigra var. henonis, P. reticulata, P. edulis, P. glauca, P. heteroclada, P. makinoi, P. nidularia, P. nigra, P. sulphurea, P. violascens and P. sulphurea f. robertii, more preferably P. nigra; the P. nigra is preferably the bamboo stalk, bamboo leaf and / or bamboo whip of P. nigra, more preferably the bamboo stalk; the particle size of the plant of the genus Phyllostachys is preferably 20 to 60 meshes, more preferably 20 to 40 meshes; if the particle size of the plant of the genus Phyllostachys does not meet the above range, it is also preferably crushed; the present invention has no special limitation on the crushing, as long as the desired particle size is achieved.
[0053] In the present invention, the mass volume ratio of the Phyllostachys plant to ethanol is preferably 1 kg:(3-5) L, more preferably 1 kg:4 L.
[0054] In the present invention, the leaching preferably includes: first leaching with a first ethanol solution, and then leaching with a second ethanol solution; the volume fraction of ethanol in the first ethanol solution is preferably 90% to 100%, more preferably 95%; the volume fraction of ethanol in the second ethanol solution is preferably 70% to 80%, more preferably 75%; the temperature of the first leaching and the second leaching is preferably room temperature, more preferably 10 to 35°C; the material-liquid ratio of the first leaching and the second leaching is independently preferably 1kg: (3 to 5) L, more preferably 1kg: 4L; the number of the first leaching is preferably 1 to 2 times, the number of the second leaching is preferably 2 to 3 times, the time of each leaching is preferably 20 to 30 hours, more preferably 24 hours, and stirring is preferably performed every 6 hours during the leaching process.
[0055] In the present invention, the method for removing ethanol is preferably vacuum concentration, and the temperature of the vacuum concentration is preferably 45°C; the present invention has no special requirements for the pressure of the vacuum concentration, and the common methods used by those skilled in the art can be used.
[0056] After obtaining the alcohol extract, the present invention dissolves and resuspends the alcohol extract in water, extracts with butanol, and concentrates to obtain a butanol extract.
[0057] In the present invention, the water is preferably distilled water. The present invention has no special requirements on the amount of water used, and the amount commonly used by those skilled in the art can be used.
[0058] In the present invention, the butanol is preferably water-saturated n-butanol, the number of extractions is preferably 2 to 5 times, more preferably 3 to 4 times; the volume ratio of the butanol to the alcohol extract suspension is preferably 1 to 3:1, the alcohol extract suspension is obtained by dissolving and resuspending the alcohol extract in water, the concentration method is preferably reduced pressure concentration, and the temperature of the reduced pressure concentration is preferably 45°C; the present invention has no special requirements for the pressure of the reduced pressure concentration, and the common methods used by those skilled in the art can be used.
[0059] In the present invention, the concentration can remove n-butanol, and the concentration preferably further includes freeze drying, and the freeze drying pressure is preferably 0 to 10 Pa; the freeze drying temperature is preferably -70 to -80°C.
[0060] After obtaining the butanol extract, the invention separates the butanol extract using a macroporous adsorption resin column, eluting with water, a 20% volume fraction ethanol solution, and a 40% volume fraction ethanol solution in sequence, collecting and concentrating the eluents, respectively, to obtain a 20% ethanol fraction and a 40% ethanol fraction.
[0061] In the present invention, the macroporous adsorption resin column preferably includes an HP-20 column or an AB-8 column.
[0062] In the present invention, the mass of the macroporous resin in the macroporous adsorption resin column is preferably 8 to 16 times the mass of the butanol extraction; and the butanol extract is preferably mixed with water before being separated by the macroporous adsorption resin column, and the water is preferably distilled water.
[0063] In the present invention, the usage amounts of water, 20% volume fraction ethanol solution and 40% volume fraction ethanol solution are preferably 2-3 BV, 2-3 BV and 2-3 BV respectively.
[0064] After obtaining the 20% ethanol fraction and the 40% ethanol fraction, the present invention separates the 20% ethanol fraction through a first ODS chromatographic column, and sequentially elutes with 5% volume fraction ethanol solution, 10% volume fraction ethanol solution, 15% volume fraction ethanol solution, 20% volume fraction ethanol solution, 25% volume fraction ethanol solution, 30% volume fraction ethanol solution, 50% volume fraction ethanol solution, and 100% ethanol, with each gradient elution of 2 to 3 BV, each 0.1 to 0.3 BV being a fraction, combining the same fractions, and concentrating to obtain components A1 to A10;
[0065] The 40% ethanol portion was separated by a second ODS chromatographic column, and eluted with 20% volume fraction ethanol solution, 30% volume fraction ethanol solution, 35% volume fraction ethanol solution, 40% volume fraction ethanol solution, 45% volume fraction ethanol solution, 50% volume fraction ethanol solution, 60% volume fraction ethanol solution, 80% volume fraction ethanol solution, and 100% ethanol in sequence, with each gradient elution being 2 to 3 BV, and each 0.1 to 0.3 BV being a fraction. The same fractions were combined and concentrated to obtain components B1 to B9.
[0066] In the present invention, the fillers of the ODS chromatographic columns used for the first ODS chromatographic column separation and the second ODS chromatographic column separation are preferably ODS-A (12 nm S-50 μm).
[0067] The present invention performs a first gel column chromatography separation on the A3 component, the mobile phase is water, each 1 / 20 times BV (column volume) is a fraction, the same fractions are combined to obtain 19 elution parts, which are represented by a to s in sequence, and fractions e and h are respectively concentrated to obtain A3e component and A3h component;
[0068] The B1 component was subjected to a second gel column chromatography separation with water as the mobile phase. Every 1 / 20 times of BV was a fraction. The same fractions were combined to obtain 15 elution parts, which were represented by a to o in sequence. Fraction h was concentrated to obtain component B1h.
[0069] In the present invention, the fillers of the gel chromatography columns of the first gel column chromatography separation and the second gel column chromatography separation are preferably Sephadex LH-20.
[0070] In the present invention, the A3e component is dissolved in water, separated by a first preparative chromatography column, and isocratically eluted with a 15% volume fraction methanol solution to obtain compound 1;
[0071] A3h was dissolved in water, and separated by a second preparative chromatography column, and isocratically eluted with a 13% volume fraction acetonitrile solution to obtain compound 3;
[0072] B1h was dissolved in water, and separated by a third preparative chromatography column, and isocratically eluted with a 15% volume fraction methanol solution to obtain compound 2.
[0073] In the present invention, the preparative chromatographic columns for separation by the first preparative chromatographic column, separation by the second preparative chromatographic column and separation by the third preparative chromatographic column are preferably ODS-AQ (250×20 mm; 12 nm). The detection wavelength for separation by the first preparative chromatographic column is preferably 251 nm, the detection wavelength for separation by the second preparative chromatographic column is preferably 239 nm, and the detection wavelength for separation by the third preparative chromatographic column is preferably 277 nm.
[0074] The present invention also provides the use of the phenylpropanoid compounds described in the above technical scheme or the phenylpropanoid compounds obtained by the above preparation method in the preparation of drugs for treating nervous system diseases or cardiovascular diseases.
[0075] The present invention predicts the biological activity of the obtained new compounds based on the reverse virtual screening technology of structure and pharmacophore, and finds that the new compounds 1 to 3 have therapeutic effects on nervous system diseases and cardiovascular diseases.
[0076] In order to further illustrate the present invention, the phenylpropanoid compounds provided by the present invention and their preparation methods and applications are described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.
[0077] Example 1
[0078] Separation and preparation method of phenylpropanoid compounds in Phyllostachys pubescens:
[0079] 1) Collect fresh bamboo stalks of P. nigra var. henonis, remove leaves, cut into bamboo pieces with a width of less than 3 cm, and crush with a hammer mill. Take 53 kg of bamboo stalk powder, first extract it once with 95% volume fraction ethanol solution at room temperature at a solid-liquid ratio of 1:4 (m:v, kg:L), filter it, and then extract the residue with 75% ethanol twice, each time for 24 hours, stir it every 6 hours, and concentrate the filtrate under reduced pressure at 45°C to obtain 2246 g of P. nigra var. henonis bamboo stalk extract.
[0080] 2) The extract of the bamboo stalk of Phyllostachys pubescens was dissolved and resuspended in distilled water, and then extracted four times with water-saturated n-butanol at an extraction volume ratio of 1:1 (v:v). The n-butanol phase was concentrated under reduced pressure at 45° C. and freeze-dried to obtain 446 g of n-butanol phase extract.
[0081] 3) The n-butanol phase extract was dissolved and resuspended in distilled water, and separated by macroporous resin AB-8. Distilled water (2BV), 20% ethanol (3BV), and 40% ethanol (3BV) were used as mobile phases for elution. The 20% ethanol and 40% ethanol eluates were concentrated under reduced pressure to obtain a 20% ethanol fraction (61 g) and a 40% ethanol fraction (86 g), respectively.
[0082] 4) The 20% ethanol fraction was dissolved with ethanol, adsorbed by C18 filler ODS-A (12nm S-50μm), evaporated and removed the solvent, and then dry-packed on a column, and separated by medium-pressure preparative chromatography (Sepacore X10). Eluted with 5%, 10%, 15%, 20%, 25%, 30%, 50%, and 100% ethanol in sequence. When no chromatographic peak appeared at 254nm, the mobile phase was replaced with the next concentration; after detection by a photodiode array detector (PDAD), the same fractions were combined to obtain A1 to A10, a total of 10 fractions. The A3 fraction was concentrated under reduced pressure to obtain 10.2g of A3.
[0083] The 40% ethanol fraction was dissolved with ethanol, adsorbed by C18 filler ODS-A (12nm S-50μm), evaporated and removed the solvent, and then dry-packed on a column, and separated by medium-pressure preparative chromatography (Sepacore X10). Eluted with 20%, 30%, 35%, 40%, 45%, 50%, 60%, 80%, and 100% ethanol in sequence. When no chromatographic peak appeared at 254nm, the mobile phase was replaced with the next concentration. After PDAD detection, the same fractions were combined to obtain B1 to B9, a total of 9 fractions. The B1 fraction was concentrated under reduced pressure to obtain 42.0g of B1.
[0084] 5) A3 was dissolved in distilled water and separated by chromatography on a Sephadex LH-20 column. The loading amount was 1% of the volume of the gel column. Each 1 / 20 column volume was a fraction. After PDAD detection, the same fractions were combined to obtain a total of 19 fractions, which were represented by letters a to s. Fractions e and h were concentrated under reduced pressure to obtain component A3e (588.8 mg) and component A3h (591.6 mg), respectively.
[0085] B1 was dissolved in distilled water and separated by chromatography on a Sephadex LH-20 column. The loading amount was 1% of the volume of the gel column. Each 1 / 20 column volume was a fraction. After PDAD detection, the same fractions were combined to obtain a total of 15 fractions, which were represented by letters a to o. Fraction h was concentrated under reduced pressure to obtain B1h (3110.1 mg).
[0086] 6) A3e was dissolved in 10 mL of distilled water and prepared by semi-preparative liquid chromatography (Shimadzu), the chromatographic column was ODS-AQ (250×20 mm; 12 nm), the mobile phase was 15% methanol, isocratic elution, the detection wavelength was 251 nm, and the new phenylpropanoid compound 1 (12.8 mg) was prepared by repeated accumulation. The HPLC purity test conditions were: the chromatographic column was ODS-AQ (250×4.6 mm; 12 nm), 15% methanol isocratic, the flow rate was 1 mL / min, the full wavelength (200-400 nm), and the retention time was 31.8 min.
[0087] A3h was dissolved in 10 mL of distilled water and prepared by semi-preparative liquid chromatography (Shimadzu), the chromatographic column was ODS-AQ (250×20 mm; 12 nm), the mobile phase was 13% acetonitrile, isocratic elution, the detection wavelength was 239 nm, and the new phenylpropanoid compound 3 (7.0 mg) was prepared by repeated accumulation. The HPLC purity test conditions were: the chromatographic column was ODS-AQ (250×4.6 mm; 12 nm), 13% acetonitrile isocratic, the flow rate was 1 mL / min, the full wavelength (200-400 nm), and the retention time was 17.1 min.
[0088] B1h was dissolved in 10 mL of distilled water and prepared by semi-preparative liquid chromatography (Shimadzu), the chromatographic column was ODS-AQ (250×20 mm; 12 nm), the mobile phase was 15% methanol, isocratic elution, the detection wavelength was 277 nm, and the new phenylpropanoid compound 2 (71.4 mg) was prepared by repeated accumulation. The HPLC purity test conditions were: the chromatographic column was ODS-AQ (250×4.6 mm; 12 nm), 15% methanol isocratic, the flow rate was 1 mL / min, the full wavelength (200-400 nm), and the retention time was 34.9 min.
[0089] Test Example 1 Structural Identification of New Phenylpropanoid Compounds
[0090] 1. Structural identification of compound 1, its chemical formula is:
[0091]
[0092] Table 1 NMR data of compound 1 (DMSO-d6)
[0093]
[0094]
[0095] UV(H2O)λ max (logε)251.0nm HRESIMS m / z:703.2092[M+HCOO] - , (calculated for 703.2091). High-resolution mass spectrometry and nuclear magnetic resonance data suggest that the molecular formula of compound 1 is C 29 H 38 O 17 The unsaturation degree is 11. The H NMR spectrum data showed that compound 1 contained 7 aromatic ring hydrogen signals, namely δ H 7.90 (dd, 9.0, 1.4 Hz, 2H), δ H 7.15 (dd, 9.0, 1.4 Hz, 2H), δ H 7.00(d,8.4Hz,1H),δ H 6.95(s,1H) and δ H 6.71 (d, 8.5 Hz, 1H). H 7.15 and δ H The coupling constants of 7.90 are 9.0 Hz and 1.4 Hz, corresponding to 3 J and 4 J, forming the AA'BB' spin coupling system of the para-substituted benzene ring. H 7.00, δ H 6.95, δ H 6.71 constitutes another ABX spin coupling system of benzene ring. H 3.73 (s, 3H) is the methoxy signal, δ H 5.04 (d, 8.0 Hz, 1H) and δ H 4.94 (d, 6.5 Hz, 1H) are two anomeric hydrogen signals, indicating that the compound contains two β-D-glucose units. H 4.45 (d, 4.8 Hz 1H), δ H There are two oxygen-containing methines at 3.43-3.46 (m, 1H). H 3.10-3.17 (m 1H) and δ H There is an oxygen-containing methylene group at 3.34 (overlap, 1H). The C NMR spectrum data show that δ C 165.2 (carbonyl), δ C 161.2, δC 131.2, δ C 123.0 and δ C 116.0 is the carbon signal of the p-substituted benzoic acid unit, δ C 148.3, δ C 145.1, δ C 137.4, δ C 118.6, δ C 114.5, δ C 111.1, δ C 75.9, δ C 72.7, δ C 62.6 and δ C 55.6 (methoxy) is the carbon signal of 1'3'4'-trisubstituted arylglycerol unit. Combined with HSQC data, two β-D-glucose unit signals were determined, δ C 99.7 (anomeric carbon), δ C 77.1, δ C 76.7, δ C 73.2, δ C 69.6, δ C 60.6 constitutes glucose ring A; δ C 99.9 (anomeric carbon), δ C 76.5, δ C 73.8, δ C 73.2, δ C 70.0, δ C 64.0 constitutes glucose ring B. From the key data of the HMBC spectrum, it can be seen that H-1"' / C-4 and H-1" / C-4' are related, suggesting that the two glucose units are connected at the C-4 and C-4' positions respectively. In addition, H-6" / C-7 is related, indicating that the C-6" of the β-D-glucose unit is connected to C-7 through a COC bond. δ H 7.90(H-2, H-6) / δ C 165.2 (C-7), suggesting that C-1 is connected to C-7 of the benzene ring. H 3.73 / δ C 148.3 correlation, suggesting that the methoxy group is connected to the C-3' position. H-7' / C-2', H-7' / C-6' correlation, suggesting that the glycerol unit is connected to C-1'. In summary, the planar structure of compound 1 is guaiacylglycerol4'-O-β-D-[6"-O-(4-O-β-D-glucopyranosyl)-p-hydroxylbenzoyl]-glucopyranoside. In addition, due to the Δδ C8' -C7' The value is 3.2>2ppm, and the CD data show that compound 1 has a negative Cotton effect at 228nm. Therefore, the absolute configuration of compound 1 is (7'R,8'R)guaiacylglycerol4'-O-β-D-[6"-O-(4-O-β-D-glucopyranosyl)-p-hydroxylbenzoyl]-glucopyranoside.
[0096] 2. Structural identification of compound 2, its chemical structure is:
[0097]
[0098] Table 2 NMR data of compound 2 (DMSO-d6)
[0099]
[0100]
[0101] UV(MeOH)λ max (logε)275.9nm; HRESIMS m / z:555.1716[MH] - , (calculated for 555.1719). High-resolution mass spectrometry and nuclear magnetic resonance data suggest that the molecular formula of the compound is C 25 H 32 O 14 The unsaturation degree is 10. The hydrogen spectrum data showed that compound 2 contained 5 aromatic ring hydrogen signals δ H 7.22(s,2H),δ H 6.95(d,1.8Hz,1H),δ H 7.00 (d, 8.5 Hz, 1H) and δ H 6.61 (dd, 8.5, 1.8 Hz, 1H), one anomeric hydrogen signal δ H 4.95 (d, 7.0 Hz, 1H), two oxygen methylene hydrogen signals δ H 4.40 (d, 4.9 Hz, 1H) and δ H 3.38-3.46 (m, 1H), one oxymethylene δ H 3.08-3.17 (m, 1H), δ H 3.29-3.31 (m, 1H), three methoxy groups δ H 3.80 (s, 6H) and δ H 3.72 (s, 3H). The carbon spectrum data showed that there were 22 signals, which, combined with the HSQC data, belonged to a glycerol unit δ C72.7, δ C 75.9 and δ C 62.6, one β-D-glucose unit δ C 100.0 (anomeric carbon), δ C 73.2, δ C 76.6, δ C 70.1, δ C 73.9 and δ C 64.2, three methoxyl groups C 56.2 and δ C 55.6, a carbonyl δ C 165.5, two benzene rings δ C 119.2, δ C 107.1, δ C 147.6, δ C 140.9, δ C 165.5, δ C 137.3, δ C 111.1, δ C 148.3, δ C 145.3, δ C 114.1 and δ C 118.5. Compared with the hydrogen and carbon spectrum data of compound 1, it can be seen that compound 2 is a similar compound to compound 1. Combined with the HMBC spectrum, the structural difference from compound 1 is that compound 2 has one less anomeric hydrogen and two more methoxy groups. H 3.8 (s, 6H), the methoxy group is respectively with C-3 (δ C 147.6) and C-5 (δ C 147.6). This indicates that compound 2 has two more methoxy groups on the p-substituted benzoic acid unit and one less D-glucose unit. Therefore, the planar structure of compound 2 is guaiacylglycerol 4'-O-β-D-[6"-O-3,5-dimethoxy-4-hydroxylbenzoyl]-glucopyranoside. In addition, the Δδ 8'-C7' The value is 2.7>2ppm, indicating that the relative configuration of compound 2 is threoguaiacylglycerol. CD data show a negative Cotton effect at 230nm, indicating that the C-7' and C-8' configurations of compound 2 are 7'R and 8'R. Therefore, the absolute configuration of compound 2 is (7'R,8'R)guaiacylglycerol 4'-O-β-D-[6"-O-3,5-dimethoxy-4-hydr oxylbenzoyl]-glucopyranoside.
[0102] 3. The structural identification of compound 3, its chemical structure is:
[0103]
[0104] Table 3 NMR data of compound 3 (DMSO-d6)
[0105]
[0106]
[0107] UV(H2O)λ max (logε)277.1nm HRESIMS m / z:527.1759[MH] - (calculated for 527.1770). High-resolution mass spectrometry and nuclear magnetic resonance data suggest that the molecular formula of the compound is C 24 H 32 O 13 The unsaturation degree is 9. The hydrogen spectrum data showed that compound 3 contained 4 aromatic ring hydrogen signals δ H 6.91 (d, J = 1.7, 1H), δ H 6.72 (dd, J = 8.1, 1.7, 1H), δ H 6.69 (d, J = 8.1, 1H), δ H 6.39 (d, J = 1.1, 2H). According to the coupling constant, the first three aromatic ring hydrogen signals constitute a typical ABX spin coupling system. The integral of the fourth aromatic ring hydrogen signal peak is about 2, indicating that the signal contains two hydrogen atoms and is coupled to each other. The coupling constant is 1.1 Hz, indicating that 4 J coupling, forming another AB spin coupling system. Three methoxyl signals δ H 3.72(s,6H),δ H 3.74 (s, 3H). One anomeric hydrogen 4.77 (d, 7.4, 1H), suggesting that compound 3 contains a D-glucose linked by a β-glycosidic bond. Two oxygen-containing methine signals δ H 4.78 (d, 8.0, 1H) and δ H 3.94-4.02 (m, 1H), one oxygen-containing methylene δ H 3.37-3.39 (m, 1H), δ H 3.64-3.68 (m, 1H). Carbon spectrum data showed that compound 3 contained two methoxy signals δ C 55.9, δ C 55.5, where δ CThe signal intensity of 55.9 is about twice that of the latter, and it is speculated that there are three methoxy groups, which is consistent with the results of hydrogen spectrum data analysis. C 153.8, δ C 153.0, δ C 147.0, δ C 145.3, δ C 133.4, δ C 130.1, δ C 119.3, δ C 114.7, δ C 110.9 and δ C 94.4. A D-glucose δ C 101.0 (anomeric carbon), δ C 77.3, δ C 76.8, δ C 73.3, δ C 70.1 and δ C 60.9. One glycerol unit δ C 86.3, δ C 72.0 and δ C 59.6. The HMBC key long-range correlation data suggest that H-1" / C-4' is correlated, indicating that the β-D-glucose unit is connected to C-4' of the benzene ring. The three methoxy groups are correlated to C-2', C-6' and C-3, respectively, suggesting that they are connected to C-2', C-6' and C-3, respectively. H-7 / C-2 and H-7 / C-6 are correlated, suggesting that the oxygen-containing carbon C-7 of the glycerol unit is connected to C-1. In addition, H-8 / C-1' is correlated, indicating that the oxygen-containing carbon C-8 of the glycerol unit is connected to C-1' through a COC bond. Therefore, the planar structure of compound 3 is guaiacylglycerol8-O-1'-neolignan-4'-O-β-D-glucopyranoside. The Δδ C7-C8 The value is 14.3ppm, and the CD data show a negative Cotton effect at 234nm, indicating that the absolute configurations of C-7 and C-8 of compound 3 are 7R and 8R. Therefore, compound 3 is (7R, 8R)guaiacylglycerol8-O-1'-neolignan-4'-O-β-D-glucopyranoside.
[0108] Application Example 1 Virtual Screening of Biological Activities of New Phenylpropanoid Compounds
[0109] The reverse virtual screening technology based on pharmacophore model and structure was used to predict the biological activities of three new compounds. The 3D structural models of the three new compounds were constructed using Chemdraw 20.0, and the energy was minimized by MM2 force field. The target prediction and screening were performed based on PharmMapper (z score>0.8), SEA (z score>10), Super-Pred (probability>60%; Model accuracy>80%), NetInfer (score>0.8), and SwissTargetPrediction databases. All database parameters selected the default options to generate target information for the three new compounds. The results of the five databases were merged, and the duplicate targets were removed to obtain the predicted biological activity targets of the three new compounds.
[0110] The STRING database was used to predict the protein-protein interaction (PPI) network. The species was set as Homo sapiens to obtain protein interaction information. The topological index was calculated by Cytoscape (V3.10.2), and the protein interaction network was constructed according to the degree. The top 20 key targets were screened by the MCC algorithm, and the key subnetworks were obtained by calculating the betweenness centrality (BC), closeness centrality (CC), degree centrality (DC), eigenvector centrality (EC), and the method based on the local average connectivity (LAC) based on the MCODE algorithm.
[0111] For the new compound 1, GAPDH is the most critical target among the key targets, with an MCC value of 1.52E+08. In the key subnetwork, FGF2 is the core target and the center of the network. GAPDH is also in a core position in the subnetwork. By merging the key target set with the targets in the key subnetwork and removing duplicates, the core targets are as follows: IGF1, NFKB1, GAPDH, HIF1A, FGF2, HRAS, MMP9, and PIK3R1.
[0112] Similarly, the core targets calculated for new compounds 2 and 3 were: NFKB1, TLR4, ALB, HIF1A; FGF2, HIF1A, ALB, STAT1, HSP90AA1, JAK2, IL2, PDGFRA, HRAS, CDC42.
[0113] Table 4 Topological values of key protein target interactions of new compound 1
[0114]
[0115]
[0116] Table 5 Topological values of key target sites for protein interaction of new compound 2
[0117] Target MCC BC CC DC EC LAC IGF1R 1.48E+06 0.62 0.82 11.00 0.24 9.45 HSP90AA1 3.36E+06 4.38 1.00 14.00 0.29 10.71 PTPN1 8.15E+05 0.42 0.78 10.00 0.22 8.60 RHOA 1.28E+06 0.92 0.82 11.00 0.24 9.27 MET 1.19E+06 0.20 0.78 10.00 0.22 8.80 NFKB1 3.67E+06 32.93 0.94 14.00 0.35 6.80 TLR4 2.03E+06 13.57 0.80 11.00 0.31 6.67 CDC42 2.01E+06 2.42 0.93 13.00 0.28 10.46 GSK3B 2.32E+06 2.42 0.93 13.00 0.28 10.46 ALB 3.06E+06 29.43 0.94 14.00 0.36 7.07 IL6 3.68E+06 4.38 1.00 14.00 0.29 10.71 TLR2 1.75E+06 0.50 0.78 10.00 0.22 8.60 NOS2 8.57E+05 0.00 0.70 8.00 0.18 7.00 STAT1 2.07E+06 2.44 0.88 12.00 0.26 9.50 HIF1A 2.47E+06 12.53 0.76 13.00 0.27 5.82
[0118] Table 6 Topological values of key protein target interactions of new compound 3
[0119]
[0120]
[0121] Table 7 Topological values of key subnetworks of protein interactions of new compound 1
[0122] Target Points Node Status BC CC DC EC LAC FGF2 9.11 Seed 5.51 0.77 12.00 0.27 8.50 PLAT 8.00 Clustered 0.00 0.63 7.00 0.17 6.00 SERPINE1 7.35 Clustered 1.15 0.71 10.00 0.24 8.20 SOD2 9.00 Clustered 1.07 0.65 8.00 0.19 6.25 HIF1A 7.59 Clustered 15.94 0.89 15.00 0.31 8.80 MMP13 9.00 Clustered 0.57 0.68 9.00 0.22 7.56 CCR1 7.56 Clustered 0.00 0.59 5.00 0.13 4.00 GAPDH 7.97 Clustered 20.64 0.94 16.00 0.32 9.00 NFKB1 8.48 Clustered 22.84 0.94 16.00 0.32 8.75 NOX1 7.82 Clustered 0.00 0.61 6.00 0.14 5.00 IGF1 8.04 Clustered 13.93 0.85 14.00 0.29 8.43 CCL5 7.72 Clustered 4.18 0.74 11.00 0.25 8.00 IL2 7.70 Clustered 5.22 0.74 11.00 0.25 7.64 CDK6 9.00 Clustered 0.57 0.61 6.00 0.14 4.33 PIK3R1 7.63 Clustered 1.32 0.63 7.00 0.16 4.86 MMP9 8.57 Clustered 22.87 0.94 16.00 0.32 8.75 NFE2L2 8.31 Clustered 1.38 0.65 8.00 0.18 6.00 HRAS 8.94 Clustered 2.80 0.68 9.00 0.20 6.22
[0123] Table 8 Topological values of key subnetworks of protein interactions of new compound 2
[0124] Target Points Node Status BC CC DC EC LAC CD209 7.82 Seed 0.00 0.64 7.00 0.22 6.00 SELP 6.77 Clustered 1.83 0.67 8.00 0.23 6.00 LGALS3 6.51 Clustered 1.13 0.67 8.00 0.24 6.25 ESR2 7.82 Clustered 0.33 0.59 5.00 0.14 3.60 TLR4 6.38 Clustered 13.57 0.80 12.00 0.31 6.67 ARG2 7.00 Clustered 1.23 0.62 6.00 0.17 4.00 NFKB1 6.32 Clustered 32.93 0.94 15.00 0.35 6.80 CDK2 7.56 Clustered 0.73 0.59 5.00 0.15 3.20 KIT 7.54 Clustered 5.60 0.70 9.00 0.25 5.56 PIK3CB 7.13 Clustered 0.00 0.57 4.00 0.13 3.00 HPRT1 7.00 Clustered 0.00 0.62 6.00 0.20 5.00 IL2 7.31 Clustered 23.73 0.89 14.00 0.34 6.86 HIF1A 6.41 Clustered 12.53 0.76 11.00 0.27 5.82 DPP4 7.42 Clustered 2.63 0.67 8.00 0.23 5.75 PLAU 6.56 Clustered 0.00 0.57 4.00 0.14 3.00 SLC2A1 7.82 Clustered 2.30 0.64 7.00 0.20 4.57 ALB 6.31 Clustered 29.43 0.94 15.00 0.36 7.07
[0125] Table 9 Topological values of key subnetworks of protein interactions of new compound 3
[0126]
[0127]
[0128] DAVID (Updated on April 17, 2024) was used to perform gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis on the predicted targets, and enrichment analysis based on DisGeNET and PaGenBase databases was performed. GO entries and KEGG pathways with p-values < 0.01 were considered significantly enriched, and the most critical biological activity information of the three compounds was obtained.
[0129] Among them, the new compound 1 mainly participates in biological processes such as single-organism metabolism, reaction to organic matter, reaction to chemical substances, reaction to oxygen-containing compounds, etc., and has biological functions such as catalytic activity, small molecule binding, same protein binding, hydrolase activity, etc., and the sites of action include extracellular exosomes, vesicles, extracellular vesicles, plasma membrane parts, etc. ( Figure 1 ). The action pathways are neuroactive ligand-receptor interactions, metabolic pathways, starch and sucrose metabolism, HIF-1 signaling pathway, prostate cancer, calcium signaling pathway, central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, carbohydrate digestion and absorption, lipids and atherosclerosis, cancer pathways, nucleotide metabolism, cAMP signaling pathway, melanoma, saliva secretion, Ras signaling pathway, chemical carcinogenesis-receptor activation, T cell receptor signaling pathway, galactose metabolism, Rap1 signaling pathway, etc. ( Figure 2 ). The results of enrichment analysis of the DisGeNET database showed that the new compound 1 may be effective in the following diseases: diabetes-experimental, neuralgia, endothelial dysfunction, myocardial ischemia, cognitive impairment, etc. ( Figure 3 ). The results of enrichment analysis of the PaGenBase database showed that the cells or tissues that the new compound 1 may act on include: liver, DRG cells, adipocytes, HEPG2 cells, etc.
[0130] New compound 2 mainly participates in biological processes such as single-organism metabolism, reaction to oxygen-containing compounds, reaction to chemical substances, biological quality control, etc. It has biological functions such as catalytic activity, transmembrane signal transduction receptor activity, transmembrane receptor activity, signal receptor activity, etc., and its sites of action include vesicles, extracellular exosomes, secretory granules, plasma membrane parts, etc. ( Figure 4 ). The action pathways include neuroactive ligand-receptor interaction, metabolic pathways, carbohydrate digestion and absorption, chemical carcinogenesis-receptor activation, etc. ( Figure 5 ). The results of enrichment analysis of the DisGeNET database showed that the diseases that the new compound 2 may be effective for include: neuralgia, diabetes-experimental, lung disease, myocardial ischemia, memory impairment, cognitive impairment, etc. ( Figure 6 ). The results of enrichment analysis of the PaGenBase database showed that the cells or tissues that the new compound 2 may act on include: liver group, HEPG2 cells, lungs, DRG cells, etc.
[0131] New compound 3 mainly participates in biological processes such as single-organism metabolism, reaction to chemical substances, reaction to oxygen-containing compounds, reaction to organic matter, etc. It has biological functions such as catalytic activity, ion binding, signal transduction activity, transmembrane signal transduction receptor activity, etc., and its sites of action include plasma membrane, vesicles, extracellular exosomes, extracellular vesicles, etc. ( Figure 7 ). The action pathways include neuroactive ligand-receptor interaction, metabolic pathways, lipids and atherosclerosis, fluid shear stress and atherosclerosis, etc. ( Figure 8 ). The results of enrichment analysis of the DisGeNET database showed that the new compound 3 may be effective in the following diseases: reperfusion injury, neuralgia, cerebral infarction, idiopathic pulmonary hypertension, etc. ( Fig. 9 ). The results of PaGenBase database enrichment analysis showed that the cells or tissues that new compound 3 may act on include liver, HEPG2 cells, caudate nucleus, lymphoma cells, etc.
[0132] The comprehensive analysis results showed that the new compound 1 was mainly involved in metabolism-related biological processes, such as single-organism metabolic processes, reactions to organic matter, reactions to chemicals, reactions to oxygen-containing compounds, small molecule metabolic processes, reactions to organic nitrogen compounds, reactions to nitrogen compounds, etc. These processes involve multiple aspects such as cellular energy metabolism, material transport and stress response, suggesting that the new compound 1 may maintain cell homeostasis by regulating cell metabolism and affect cell growth, proliferation and survival. Secondly, the core target analysis revealed the possible mechanism of action of the new compound 1. Core targets such as insulin-like growth factor 1 (IGF1), nuclear factor NF-κB p105 subunit (NFKB1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxia-inducible factor 1-α (HIF1A), fibroblast growth factor 2 (FGF2), HRas oncogene, matrix metalloproteinase 9 (MMP9) and phosphatidylinositol 3-kinase regulatory subunit 1 (PIK3R1) are involved in multiple biological processes such as cell growth, proliferation, differentiation, apoptosis, angiogenesis, inflammatory response and cell response to hypoxia. These targets are associated with a variety of signaling pathways, such as the Ras signaling pathway, HIF-1 signaling pathway, calcium signaling pathway, EGFR tyrosine kinase inhibitor resistance pathway, etc., indicating that new compound 1 may affect cell function and cell fate by regulating these signaling pathways. DisGeNET database analysis predicts that new compound 1 may act on a variety of diseases, such as diabetes, neuralgia, endothelial dysfunction, myocardial ischemia, lung disease, diabetic retinopathy, vascular disease, hyperalgesia, retinal disease, reperfusion injury, hypercholesterolemia, cerebral infarction, subarachnoid hemorrhage, head and neck cancer, status epilepticus, idiopathic pulmonary hypertension, neuropathy, herpes simplex infection, cognitive impairment, etc. These prediction results are closely related to the biological functions, core targets and involved signaling pathways of new compound 1, further supporting its potential therapeutic application value. The analysis results of the PaGenBase database showed that the new compound 1 may act on a variety of cells or tissues, such as liver, dorsal root ganglion cells, adipocytes, liver cancer cells HepG2, human umbilical vein endothelial cells, caudate nucleus, thymus, retinoblastoma, smooth muscle, placenta, etc., suggesting that it may have a wide tissue distribution and biological effects.
[0133] The reverse virtual screening results of new compound 2 revealed that it may have therapeutic effects on various diseases through a multi-target synergistic regulatory mechanism. Its biological activity is mainly reflected in regulating cell metabolism, signal transduction and immune response, thereby affecting cell function and cell fate, providing new possibilities for the treatment of various diseases. The results of gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis showed that new compound 2 is mainly involved in metabolism-related biological processes, such as single-organism metabolic processes, reactions to chemicals, reactions to oxygen-containing compounds, reactions to organic matter, etc., and has functions such as catalytic activity and ion binding, as well as functions related to signal transduction such as signal transducer activity and transmembrane signal transduction receptor activity. This suggests that new compound 2 may affect cell function and cell fate by regulating cell metabolism and signal transduction. Core target analysis further supports this speculation. The core targets of new compound 2 include nuclear factor NF-κBp105 subunit (NFKB1), Toll-like receptor 4 (TLR4), albumin (ALB) and hypoxia-inducible factor 1-α (HIF1A). These targets are involved in a variety of biological processes such as inflammatory response, immune regulation, cell growth, angiogenesis and cell response to hypoxia, and are associated with a variety of signaling pathways, such as neuroactive ligand-receptor interaction, lipid and atherosclerosis, cancer pathways, chemical carcinogen-receptor activation, nitrogen metabolism, cAMP signaling pathway, calcium signaling pathway, etc. Analysis of the DisGeNET database and the PaGenBase database predicted that the new compound 2 may act on a variety of diseases and tissue cells, such as reperfusion injury, neuralgia, cerebral infarction, idiopathic pulmonary hypertension, pneumonia, lung disease, diabetes, unipolar depression, myocardial ischemia, aortic aneurysm, endothelial dysfunction, periodontitis, hyperlipidemia, diabetic retinopathy, herpes simplex infection, periodontal disease, subarachnoid hemorrhage, inflammation, middle cerebral artery occlusion and other diseases, as well as liver, HEPG2 cells, caudate nucleus, lymphoma cells, adipocytes, DRG cells, bone marrow, small intestine, smooth muscle, spleen, MOLT4 cells, adrenal glands, thymus, THY cells, A204 cells, cardiomyocytes and other cells or tissues. These prediction results are closely related to the biological functions, core targets and involved signaling pathways of new compound 2, further supporting its potential therapeutic application value. For example, new compound 2 may inhibit inflammatory responses and regulate immune cell functions by regulating targets such as nuclear factor NF-κB p105 subunit and Toll-like receptor 4, thereby playing a therapeutic role in inflammatory diseases such as reperfusion injury, neuralgia, pneumonia, and periodontitis. By regulating targets such as albumin and hypoxia-inducible factor 1-α, new compound 2 may affect angiogenesis and cell growth, thereby having a therapeutic effect on cardiovascular diseases such as cerebral infarction, myocardial ischemia, aortic aneurysm, and tumors.
[0134] The results of reverse virtual screening suggest that new compound 3 may play a therapeutic role in various diseases through multi-target and multi-pathway regulatory mechanisms. The results of gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis show that new compound 3 is mainly involved in metabolism-related biological processes, such as single-organism metabolic processes, reactions to chemicals, reactions to oxygen-containing compounds, reactions to organic matter, biological quality regulation, etc., and has catalytic activity, ion binding and other functions, as well as signal transduction-related functions such as signal transducer activity and transmembrane signal transduction receptor activity. This suggests that new compound 3 may affect cell function and cell fate by regulating cell metabolism and signal transduction. Core target analysis further supports this speculation. The core targets of new compound 3 include fibroblast growth factor 2 (FGF2), hypoxia-inducible factor 1-α (HIF1A), albumin (ALB), signal transduction and activator of transcription 1 (STAT1), heat shock protein 90α family A member 1 (HSP90AA1), Janus kinase 2 (JAK2), interleukin 2 (IL2), platelet-derived growth factor receptor α (PDGFRA), HRas oncogene and cell division cycle protein 42 (CDC42). These targets are involved in a variety of cell signaling pathways, such as Ras signaling pathway, Rap1 signaling pathway, calcium signaling pathway, PI3K-Akt signaling pathway, chemokine signaling pathway, etc., and affect cell growth, proliferation, differentiation, apoptosis, angiogenesis, immunoregulation and inflammatory response. Pathway analysis results show that new compound 3 may affect cell function and cell fate by regulating multiple signaling pathways. It is speculated that new compound 3 affects cell growth, proliferation and response to hypoxia by regulating the Ras signaling pathway and the HIF-1 signaling pathway, thereby producing a therapeutic effect on diseases such as tumors. By regulating the calcium signaling pathway and the cAMP signaling pathway, the new compound 3 may affect neurotransmitter release, cell excitability and energy metabolism, thereby having a therapeutic effect on nervous system diseases and metabolic diseases. By regulating the PI3K-Akt signaling pathway and the chemokine signaling pathway, the new compound 3 may affect cell survival, migration and recruitment of immune cells, thereby having a therapeutic effect on inflammatory diseases and immune-related diseases. Analysis of the DisGeNET database and the PaGenBase database predicted that new compound 3 may act on a variety of diseases and tissue cells, such as reperfusion injury, neuralgia, cerebral infarction, idiopathic pulmonary hypertension, pneumonia, lung disease, diabetes, unipolar depression, myocardial ischemia, aortic aneurysm, endothelial dysfunction, periodontitis, hyperlipidemia, diabetic retinopathy, herpes simplex infection, periodontal disease, subarachnoid hemorrhage, inflammation, middle cerebral artery occlusion and other diseases, as well as cells or tissues such as liver, HEPG2 cells, caudate nucleus, lymphoma cells, adipocytes, DRG cells, bone marrow, small intestine, smooth muscle, spleen, MOLT4 cells, adrenal gland, thymus, THY cells, A204 cells, and cardiomyocytes.These prediction results are closely related to the biological functions, core targets and involved signaling pathways of new compound 3, further supporting its potential therapeutic application value.
[0135] The results of comprehensive reverse virtual screening analysis showed that new compound 1 may play a therapeutic role in a variety of diseases by regulating energy metabolism, signal transduction, immune response and other aspects, and its potential therapeutic application areas include diabetes and its complications, nervous system diseases, cardiovascular diseases, tumors, etc. New compound 2 may affect cell metabolism, signal transduction, immune response and other aspects through a multi-target synergistic regulatory mechanism, and its potential therapeutic application areas include nervous system diseases, cardiovascular diseases, tumors, metabolic diseases and immune-related diseases. New compound 3 may affect cell metabolism, signal transduction, immune response and other aspects through a multi-target, multi-pathway regulatory mechanism, and play a therapeutic role in a variety of diseases, and its potential therapeutic application areas include nervous system diseases, cardiovascular diseases, tumors, metabolic diseases and immune-related diseases.
[0136] New compounds 1 and 2 show certain structural similarities and differences in biological activity, suggesting the potential and complexity of multifunctional small molecules in drug development. Both contain multiple functional groups such as hydroxyl, carbonyl and aromatic rings, suggesting that they may have similar physicochemical properties and potential biological activities. However, bioinformatics analysis revealed differences in their mechanisms of action and therapeutic applications. New compound 1 is mainly involved in metabolism-related biological processes, and affects cell growth, proliferation, apoptosis, angiogenesis and cell response to hypoxia by regulating targets such as insulin-like growth factor 1, nuclear factor NF-κB p105 subunit, and hypoxia-inducible factor 1-α. Its potential therapeutic applications include diabetes and its complications, nervous system diseases, cardiovascular diseases and tumors. New compound 2 focuses more on regulating cell signal transduction and immune response. Its core targets include nuclear factor NF-κB p105 subunit, Toll-like receptor 4, albumin and hypoxia-inducible factor 1-α, and participate in inflammatory response, immune regulation, cell growth and angiogenesis. New compound 2 may have therapeutic effects on inflammatory diseases, immune-related diseases, nervous system diseases, cardiovascular diseases, and tumors by regulating signaling pathways such as neuroactive ligand-receptor interactions, lipids and atherosclerosis, cancer pathways, and chemical carcinogen-receptor activation. Although new compounds 1 and 2 both target the nuclear factor NF-κB p105 subunit and hypoxia-inducible factor 1-α, there are differences in other core targets and involved signaling pathways, suggesting that the two may have therapeutic effects on different diseases through different mechanisms. For example, new compound 1 may be more inclined to regulate cellular energy metabolism and angiogenesis, while new compound 2 is more inclined to regulate inflammatory responses and immune cell functions. Future studies should further verify its mechanism of action and therapeutic effects, and evaluate its safety through animal models and clinical trials to lay the foundation for its further drug development.
[0137] Although the above-mentioned embodiments have made a detailed description of the present invention, they are only some embodiments of the present invention, rather than all embodiments. People can also obtain other embodiments based on the embodiments of the present invention without creative work, and these embodiments all fall within the scope of protection of the present invention.
Claims
1. A phenylpropanoid compound, characterized in that: Including compound 1, compound 2 or compound 3, wherein the structural formulas of compound 1, compound 2 and compound 3 are shown in formula 1, 2 and 3 respectively; 2. The method for preparing the phenylpropanoid compound according to claim 1, characterized in that: The following steps are involved: Extracting Phyllostachys spp. plants with an ethanol solution, removing ethanol from the obtained extract to obtain an alcohol extract; Dissolving and resuspending the alcohol extract in water, extracting with butanol, and concentrating to obtain a butanol extract; The butanol extract is subjected to macroporous adsorption resin column separation, and eluted with water, 20% volume fraction ethanol solution, and 40% volume fraction ethanol solution in sequence, and the eluates are collected and concentrated to obtain a 20% ethanol fraction and a 40% ethanol fraction; The 20% ethanol fraction was separated by a first ODS chromatographic column, and eluted with 5% volume fraction ethanol solution, 10% volume fraction ethanol solution, 15% volume fraction ethanol solution, 20% volume fraction ethanol solution, 25% volume fraction ethanol solution, 30% volume fraction ethanol solution, 50% volume fraction ethanol solution, and 100% ethanol in sequence, with each gradient elution of 2 to 3 BV, and each 0.1 to 0.3 BV being a fraction, and the same fractions were combined and concentrated to obtain components A1 to A10; the 40% ethanol fraction was separated by a first ODS chromatographic column, and eluted with 5% volume fraction ethanol solution, 10% volume fraction ethanol solution, 25% volume fraction ethanol solution, 30% volume fraction ethanol solution, 50% volume fraction ethanol solution, and 100% ethanol in sequence, with each gradient elution of 2 to 3 BV, and each 0.1 to 0.3 BV being a fraction, and the same fractions were combined and concentrated to obtain components A1 to A10; The alcohol part is separated by a second ODS chromatography column, and eluted with 20% volume fraction ethanol solution, 30% volume fraction ethanol solution, 35% volume fraction ethanol solution, 40% volume fraction ethanol solution, 45% volume fraction ethanol solution, 50% volume fraction ethanol solution, 60% volume fraction ethanol solution, 80% volume fraction ethanol solution, and 100% ethanol in sequence, with each gradient elution of 2 to 3 BV, and each 0.1 to 0.3 BV is a fraction, and the same fractions are combined and concentrated to obtain B1 to B9 components; The A3 component was subjected to the first gel column chromatography separation, the mobile phase was water, and each 1 / 20 times BV was a fraction. The same fractions were combined to obtain 19 elution parts, which were represented by a to s in sequence. The fractions e and h were concentrated to obtain the A3e component and the A3h component. The B1 component was subjected to the second gel column chromatography separation, the mobile phase was water, and each 1 / 20 times BV was a fraction. The same fractions were combined to obtain 15 elution parts, which were represented by a to o in sequence. The fraction h was concentrated to obtain the B1h component. The A3e component was dissolved in water, separated by a first preparative chromatography column, and isocratically eluted with a 15% volume fraction methanol aqueous solution to obtain compound 1; A3h was dissolved in water, separated by a second preparative chromatography column, and isocratically eluted with a 13% volume fraction acetonitrile aqueous solution to obtain compound 3; B1h was dissolved in water, separated by a third preparative chromatography column, and isocratically eluted with 15% volume fraction methanol aqueous solution to obtain compound 2.
3. The preparation method according to claim 2, characterized in that: The leaching comprises: first leaching with a first ethanol solution, and then second leaching with a second ethanol solution; the volume fraction of ethanol in the first ethanol solution is 90% to 100%; the volume fraction of ethanol in the second ethanol solution is 70% to 80%.
4. The preparation method according to claim 3, characterized in that: The material-liquid ratio of the first leaching and the second leaching is independently 1 kg: (3-5) L, the number of the first leaching is 1-2 times, the number of the second leaching is 2-3 times, and the time of each leaching is 20-30 hours.
5. The preparation method according to claim 2, characterized in that: The extraction is performed 2 to 5 times; the butanol is water-saturated n-butanol; the volume ratio of the butanol to the alcohol extract suspension is 1 to 3:1, and the alcohol extract suspension is obtained by dissolving and resuspending the alcohol extract in water.
6. The preparation method according to claim 2, characterized in that: The macroporous adsorption resin column includes an HP-20 column or an AB-8 column.
7. The preparation method according to claim 6, characterized in that: The macroporous adsorption resin column is used in separation of water, 20% volume fraction ethanol solution, and 40% volume fraction ethanol solution in amounts of 2-3 BV, 2-3 BV, and 2-3 BV, respectively.
8. The preparation method according to claim 2, characterized in that: The fillers of the gel chromatography columns in the first gel column chromatography separation and the second gel column chromatography separation are both Sephadex LH-20.
9. The preparation method according to claim 2, characterized in that: The preparative chromatographic columns used for the first preparative chromatographic column separation, the second preparative chromatographic column separation and the third preparative chromatographic column separation are all ODS-AQ.
10. Use of the phenylpropanoid compound according to claim 1 or the phenylpropanoid compound obtained by the preparation method according to any one of claims 2 to 9 in the preparation of drugs for treating nervous system diseases or cardiovascular diseases.
